Navigation Links
Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
Date:4/7/2008

HAE:TSX

MONTREAL, April 7 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company, will hold its Annual General and Special Meeting of Shareholders on Wednesday, April 9, 2008 at 4 p.m. at The National Club, 303 Bay Street, Toronto, Ontario.

Presentation

Mr. Joseph Galli, Chairman and Chief Executive Officer of Haemacure, will report on accomplishments of 2007 and provide an outlook for 2008 and beyond, including a report on Haemacure's clinical programs for its two proprietary, human product candidates, a fibrin sealant and an active, topical hemostatic agent (thrombin).

Live Webcast

For those who are unable to attend in person, Haemacure will simultaneously host a live webcast of the presentation with slides, at http://events.snwebcastcenter.com/haemacure/20080409/.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant. Follow-on development will focus on surgical hemostats, adhesion prevention, regenerative medecine, drug delivery and combinations with biomaterials. Haemacure has identified eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.


'/>"/>
SOURCE Haemacure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
2. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
3. Haemacure Reports Third Quarter 2007 Results
4. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
5. Smart Balance Announces Sales Organization Appointments
6. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
7. NTMir Announces First International Research Grant for Genome Sequencing
8. Dialysis Corporation of America Announces the Development of a New Facility in Pennsylvania
9. SurgiQuest Announces First Procedure Using AirSeal(TM) Access System
10. Zimmer Announces Actions Affecting its Ohio-based Orthopaedic Surgical Products Operation
11. Escalon(R) Announces China Registration for Sonomed PacScan(R) and E/Z-Scan(R) Series of A-scan, Pachymeter and B-Scan Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... 2017 , ... Renal Support Network’s annual essay contest celebrates ... The theme “Describe a positive decision that you have made about your healthcare” ... one qualification— to have been diagnosed with chronic kidney disease. This year the ...
(Date:9/20/2017)... ... 20, 2017 , ... Announced that Clear Global ... services market) has entered into an agreement on September 1, 2017 with The ... is the first private Dental School to launch an online, accredited Post Graduate ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... social campaign, “Humans With Vaginas.” The goal is to ignite conversation via social ... personal care products. The brand has declared September “Humans with Vaginas” month, releasing ...
(Date:9/20/2017)... ... 20, 2017 , ... Recognising that in today’s busy world ... delivers positive results in just three weeks. Setting the groundwork for a healthier ... seamlessly into hectic work and family schedules, participants can lose up to 15lbs ...
(Date:9/20/2017)... ... September 20, 2017 , ... Ron Norman, CEO ... marketers this week about the value of senior executives, pointed to a quote ... in business has brought us to the present and will lead us into ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... Sept. 5, 2017  Xyntek Inc. has announced another milestone in their continued ... office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, ... ... regionally. ...
(Date:9/5/2017)... Sept. 5, 2017  Just 18 months after its ... pleased to announce the appointment of three new senior ... , Dominic Jones-Phillips and James Wright ... Tammy Wynne ... market access writers. She has over ten years, experience ...
(Date:9/1/2017)... , Sept. 1, 2017 Michael ... Solutions, Inc , highlights opportunities for growth in his ... report that Marlin Equity is seeking a buyer for ... annual award-winning 22-year-old healthcare solutions Value Added Reseller and ... "As the healthcare market ...
Breaking Medicine Technology: